|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review |
Endocrine Unit, Department of Clinical Physiopathology, Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative and Neoplastic Disorders for the Development of Novel Therapies (DENOThe), University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy
(Correspondence should be addressed to A Peri; Email: a.peri{at}dfc.unifi.it)
The endocrine and the nervous system are closely correlated throughout life, starting from the embryo and until the late stages of life. Alzheimer's disease (AD) is the most common neurodegenerative disease associated with ageing. Unfortunately, an effective way to prevent or to cure this disease does not exist, so far. There is evidence that estrogens exert neuroprotective properties, although their efficacy against AD is still a matter of debate. In 2000 a new neuroprotective gene, i.e. seladin-1 (for SELective AD INdicator-1) was identified and found to be down regulated in AD vulnerable brain regions. Seladin-1 inhibits the activation of caspase-3, a key modulator of apoptosis. This protein has also enzymatic activity. In fact, it has been demonstrated that the seladin-1 gene encodes 3-β-hydroxysterol
-24-reductase, which catalyzes the synthesis of cholesterol from desmosterol. In recent years, it has been demonstrated that an appropriate amount of membrane cholesterol determines the generation of a barrier against toxic insults and prevents the production of β-amyloid, the histopathological hallmark of AD. This review will summarize the studies that have been focused on the characterization of the biological properties of seladin-1 since its first identification. In particular, the relationship between seladin-1-mediated neuroprotection and estrogens, IGF1 and thyroid hormones, will be described and discussed.
This article has been cited by other articles:
![]() |
T. M. van Himbergen, S. Otokozawa, N. R. Matthan, E. J. Schaefer, A. Buchsbaum, M. Ai, L. J.H. van Tits, J. de Graaf, and A. F.H. Stalenhoef Familial Combined Hyperlipidemia Is Associated With Alterations in the Cholesterol Synthesis Pathway Arterioscler Thromb Vasc Biol, January 1, 2010; 30(1): 113 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Donehower Using Mice to Examine p53 Functions in Cancer, Aging, and Longevity Cold Spring Harb Perspect Biol, December 1, 2009; 1(6): a001081 - a001081. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |